These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11704433)

  • 1. Standardized ultrasound as a new method to induce platelet aggregation: evaluation, influence of lipoproteins and of glycoprotein IIb/IIIa antagonist tirofiban.
    Otto C; Baumann M; Schreiner T; Bartsch G; Borberg H; Schwandt P; Schmid-Schönbein H
    Eur J Ultrasound; 2001 Dec; 14(2-3):157-66. PubMed ID: 11704433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet glycoprotein IIb/IIIa blockade with tirofiban: effect on aggregation caused by P256, an antibody to human IIb/IIIa receptors.
    Fisher I; Robinson P; Ritter JM
    Br J Clin Pharmacol; 1999 Aug; 48(2):197-9. PubMed ID: 10417496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIb/IIIa receptor inhibitor attenuates platelet aggregation induced by thromboxane A2 during in vitro nonpulsatile ventricular assist circulation.
    Yomo T; Serna DL; Powell LL; Wang D; Wilson SE; Ishimaru S; Chen JC
    Artif Organs; 2000 May; 24(5):355-61. PubMed ID: 10848676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
    Goto S; Tamura N; Ishida H
    J Am Coll Cardiol; 2004 Jul; 44(2):316-23. PubMed ID: 15261925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiolabeled tirofiban - a potential radiopharmaceutical for detection of deep venous thrombosis.
    Darkovska-Serafimovska M; Janevik-Ivanovska E; Djorgoski I; Arsova-Sarafinovska Z; Zdravkovska M; Balkanov T; Ugresic N
    Drug Des Devel Ther; 2016; 10():2989-2996. PubMed ID: 27713618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
    Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
    Thorac Cardiovasc Surg; 2006 Apr; 54(3):162-7. PubMed ID: 16639676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses.
    Matsumoto Y; Marukawa K; Okumura H; Adachi T; Tani T; Kimura Y
    Thromb Res; 1999 Jul; 95(1):19-29. PubMed ID: 10403683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro inhibition of platelet aggregation in response to increasing concentrations of tirofiban in patients with significant renal insufficiency.
    Alam M; Gonzalez R; Delarosa A; Bobek J; Dokainish H; Lakkis N
    Am Heart Hosp J; 2009; 7(1):17-20. PubMed ID: 19742428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A; Voss R
    Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.
    Li YF; Spencer FA; Becker RC
    Am Heart J; 2002 Apr; 143(4):725-32. PubMed ID: 11923812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G
    J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
    Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
    Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
    Koster A; Kukucka M; Bach F; Meyer O; Fischer T; Mertzlufft F; Loebe M; Hetzer R; Kuppe H
    Anesthesiology; 2001 Feb; 94(2):245-51. PubMed ID: 11176088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban.
    Umemura K; Kondo K; Ikeda Y; Nakashima M
    Thromb Haemost; 1997 Nov; 78(5):1381-4. PubMed ID: 9408023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of tirofiban on fibrinogen/agonist-induced platelet shape change and aggregation.
    Jagroop IA; Mikhailidis DP
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):295-302. PubMed ID: 18445610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF
    Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.
    Ahmad S; Jeske WP; Ma Q; Walenga JM; Fareed J
    Thromb Res; 2001 Apr; 102(2):143-51. PubMed ID: 11323025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.